KarXT – Talk Bio

Actionable Insights Powered by AI

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

7 months ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.

Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial

8 months ago talkbio0Tagged AbbVie, Antipsychotic Agents, Biosciences, Emraclidine, KarXT, Muscarinic Acetylcholine Receptor, Myers, NBI-1117568, Neurocrine, Schizophrenia, squibb

Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics